Tickerdienstleistung Winston Pharmaceuticals
Seite 1 von 1 Neuester Beitrag: 25.04.21 01:55 | ||||
Eröffnet am: | 31.01.16 22:23 | von: buran | Anzahl Beiträge: | 12 |
Neuester Beitrag: | 25.04.21 01:55 | von: Birgitylfoa | Leser gesamt: | 3.953 |
Forum: | Hot-Stocks | Leser heute: | 1 | |
Bewertet mit: | ||||
A common feature of our product candidates is the use of an active ingredient which depletes or interferes with the action of a neuroactive transmitter (e.g., substance P (SP), calcitonin gene-related peptide (CGRP), histamine, serotonin), thereby decreasing the ability of sensory fibers or nerve ganglia to transmit or receive sensory stimuli and mediate inflammatory reactions.
Winston's late stage candidates include episodic cluster headache, chronic migraine headache, osteo-and rheumatoid arthritis, neuropathic pain, and pain and inflammation in inflammatory bowel disease. http://www.winstonlabs.com/productdevelopment/index.html
100 N. Fairway Drive, Suite 134
Vernon Hills, IL 60061
T: (847) 362-8200
F: (847) 362-8394
info@winstonlabs.com
http://www.winstonlabs.com/about/index.html
pharmaceutical company focused on developing and commercializing novel pain management
therapies, announced that the National Institutes of Health (NIH) has awarded Winston a grant
under the Small Business Innovation Research (SBIR) program supporting the development of
Civamide, a proprietary TRPV-1 receptor modulator, for the treatment of postherpetic neuralgia
(PHN) of the trigeminal nerve (TN). The Phase I award in the amount of approximately
$375,000 will be administered by the National Institute of Neurological Disorders and Stroke
(NINDS). http://www.winstonlabs.com/files/documents/114_winstonlabs_4-9-12.pdf